{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T20:19:14Z","timestamp":1787170754521,"version":"build-2736575974"},"reference-count":21,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T00:00:00Z","timestamp":1747785600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Type 2 diabetes mellitus (T2DM) is an independent risk factor for osteoporosis, increasing the risk of fractures and poor prognosis. Recent studies suggest that glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may play a protective role in bone metabolism. However, limited evidence exists on their effect on osteoporosis incidence in T2DM patients. This study aimed to evaluate the association between GLP-1 RA use and osteoporosis risk in a real-world cohort of elderly T2DM patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective cohort study utilized electronic medical records (EMRs) from Tangdu Hospital, Xi\u2019an, China, between January 1, 2012, and December 31, 2023. Patients with T2DM who had at least two clinical visits annually and no prior osteoporosis diagnosis (ICD-10: M80-M82) at baseline were included. The primary outcome was the incidence of osteoporosis during follow-up. Cox proportional hazards models were used to evaluate the association between GLP-1 RA use and osteoporosis risk, adjusting for age, sex, BMI, blood pressure, lipid profile, renal function, osteocalcin, vitamin D levels, HbA1c, statin use, antihypertensive medication use, and smoking status. Subgroup analyses were conducted to assess potential effect modifications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 1,845 patients with T2DM were included, of whom 676 (36.6%) developed osteoporosis during follow-up. Among the 256 patients who received GLP-1 RAs, the incidence of osteoporosis was significantly lower than in those who did not receive GLP-1 RAs (P &amp;lt; 0.01). In the fully adjusted Cox model, GLP-1 RA use was associated with a significantly reduced risk of osteoporosis compared to non-users (hazard ratio [HR] = 0.69, 95% confidence interval [CI] =0.45-0.84, P &amp;lt; 0.05). Subgroup analyses indicated that the protective effect of GLP-1 RAs was consistent across age, sex, BMI, smoking status, and antihypertensive medication use (P for interaction &amp;gt; 0.05).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In patients with T2DM, patients with treatment of GLP-1 RAs resulted in lower risks of osteoporosis than those without treatment of GLP-1 RAs. These findings support the potential bone-protective effects of GLP-1 RAs but further randomized controlled trials (RCTs) or large-scale database analyses are needed to confirm these observations and guide clinical recommendations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2025.1586589","type":"journal-article","created":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T00:11:29Z","timestamp":1747786289000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["Use of GLP-1 receptor agonist and risk of osteoporosis among patients with type 2 diabetes: a real-world study"],"prefix":"10.3389","volume":"16","author":[{"given":"Ming","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiming","family":"Lyu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingwei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianwei","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tongtao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,5,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"109119","DOI":"10.1016\/j.diabres.2023.110945","article-title":"IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045","volume":"183","author":"Sun","year":"2022","journal-title":"Diabetes Res Clin practice."},{"key":"B2","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.diabres.2017.03.024","article-title":"IDF Diabetes Atlas: Global estimates for the prevalence of diabetes for 2015 and 2040","volume":"128","author":"Ogurtsova","year":"2017","journal-title":"Diabetes Res Clin practice."},{"key":"B3","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/s11657-022-01061-5","article-title":"UK clinical guideline for the prevention and treatment of osteoporosis","volume":"17","author":"Gregson","year":"2022","journal-title":"Arch osteoporosis."},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s00264-020-04492-2","article-title":"Burden of fractures in France: incidence and severity by age, gender, and site in 2016","volume":"44","author":"Bouyer","year":"2020","journal-title":"Int orthopaedics."},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.4805","article-title":"Hip fracture risk assessment in elderly and diabetic patients: combining autonomous finite element analysis and machine learning","volume":"38","author":"Yosibash","year":"2023","journal-title":"J Bone mineral research: Off J Am Soc Bone Mineral Res"},{"key":"B6","doi-asserted-by":"publisher","first-page":"4827","DOI":"10.3390\/ijms25094827","article-title":"Links among obesity, type 2 diabetes mellitus, and osteoporosis: bone as a target","volume":"25","author":"Martiniakova","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2015.08.006","article-title":"Chronic administration of Glucagon-like peptide-1 receptor agonists improves trabecular bone mass and architecture in ovariectomised mice","volume":"81","author":"Pereira","year":"2015","journal-title":"Bone."},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.1898","article-title":"Exendin-4, a glucagon-like peptide-1 receptor agonist, prevents osteopenia by promoting bone formation and suppressing bone resorption in aged ovariectomized rats","volume":"28","author":"Ma","year":"2013","journal-title":"J Bone mineral research: Off J Am Soc Bone Mineral Res"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-019-01034-5","article-title":"Liraglutide increases bone formation and inhibits bone resorption in rats with glucocorticoid-induced osteoporosis","volume":"42","author":"Yang","year":"2019","journal-title":"J endocrinological investigation."},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-015-3279-7","article-title":"Diabetes mellitus and risk of hip fractures: a meta-analysis","volume":"27","author":"Fan","year":"2016","journal-title":"Osteoporosis international: A J established as result cooperation between Eur Foundation Osteoporosis Natl Osteoporosis Foundation USA."},{"key":"B11","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1002\/jbmr.3323","article-title":"Indications of increased vertebral fracture risk in patients with type 2 diabetes","volume":"33","author":"Starup-Linde","year":"2018","journal-title":"J Bone mineral research: Off J Am Soc Bone Mineral Res"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s00264-016-3146-y","article-title":"Increased risk of vertebral fracture in patients with diabetes: a meta-analysis of cohort studies","volume":"40","author":"Wang","year":"2016","journal-title":"Int orthopaedics."},{"key":"B13","doi-asserted-by":"publisher","first-page":"e19762","DOI":"10.1097\/MD.0000000000019762","article-title":"Prevalence of osteoporosis in patients with type 2 diabetes mellitus in the Chinese mainland: A protocol of systematic review and meta-analysis","volume":"99","author":"Si","year":"2020","journal-title":"Medicine."},{"key":"B14","article-title":"Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes\u2013a meta-analysis","volume":"18","author":"Vestergaard","year":"2007","journal-title":"Osteoporosis international: A J established as result cooperation between Eur Foundation Osteoporosis Natl Osteoporosis Foundation USA."},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-015-3660-2","article-title":"The effect of thiazolidinediones on bone mineral density and bone turnover: systematic review and meta-analysis","volume":"58","author":"Billington","year":"2015","journal-title":"Diabetologia."},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-015-3660-2","article-title":"Fracture risk associated with common medications used in treating type 2 diabetes mellitus","volume":"74","author":"Wolverton","year":"2017","journal-title":"Am J health-system pharmacy: AJHP: Off J Am Soc Health-System Pharmacists."},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1210\/en.2011-2170","article-title":"Overlap of endocrine hormone expression in the mouse intestine revealed by transcriptional profiling and flow cytometry","volume":"153","author":"Habib","year":"2012","journal-title":"Endocrinology."},{"key":"B18","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2007.03.054","article-title":"Biology of incretins: GLP-1 and GIP","volume":"132","author":"Baggio","year":"2007","journal-title":"Gastroenterology."},{"key":"B19","doi-asserted-by":"publisher","first-page":"117338","DOI":"10.1016\/j.bone.2024.117338","article-title":"Association of Glucagon-like peptide-1 receptor agonists use with fracture risk in type 2 diabetes: A meta-analysis of randomized controlled trials","volume":"192","author":"Zhang","year":"2025","journal-title":"Bone."},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1378291","article-title":"Liraglutide, a glucagon-like peptide-1 receptor agonist, inhibits bone loss in an animal model of osteoporosis with or without diabetes","volume":"15","author":"Wu","year":"2024","journal-title":"Front Endocrinol (Lausanne)."},{"key":"B21","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1186\/s12891-022-05396-5","article-title":"Glucagon-like peptide-1 attenuates diabetes-associated osteoporosis in ZDF rat, possibly through the RAGE pathway","volume":"23","author":"Cheng","year":"2022","journal-title":"BMC musculoskeletal Disord"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1586589\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T00:11:30Z","timestamp":1747786290000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1586589\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,21]]},"references-count":21,"alternative-id":["10.3389\/fendo.2025.1586589"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2025.1586589","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,21]]},"article-number":"1586589"}}